ClinicalTrials.gg
RecruitingNCT07910110ASISTUpdated Nov 2, 2026

Neurobiological Markers of Non-suicidal Self-injury and Treatment Mechanisms of Adolescent Self-injury Intervention Skills Training

An interventional study of Adolescent Self-Injury Intervention Skills Training (ASIST) and Treatment as Usual (TAU) in Non-suicidal Self-injury (NSSI) and Adolescent, sponsored by Seoul National University. Recruiting at 1 site in South Korea. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Seoul National University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 10 months after the study started (first participant enrolled Dec 2021, registered Oct 2026).
  • Started Dec 2021; still recruiting 4 years 10 months later.
Updated Nov 2, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the effectiveness and safety of Adolescent Self-Injury Intervention Skills Training (ASIST), a treatment program developed by the research team, compared with treatment as usual (TAU) in adolescents who engage in non-suicidal self-injury (NSSI).

The main questions it aims to answer are:

  1. How do the effectiveness and safety of ASIST compare with those of treatment as usual in adolescents with NSSI?
  2. How are treatment-related changes in psychological, clinical, behavioral, and biological measures associated with treatment response?
  3. Can machine learning techniques be used to predict treatment responses in adolescents with NSSI?

Researchers will compare adolescents receiving ASIST with those receiving TAU to examine changes in psychological, clinical, and behavioral characteristics before and after treatment. They will also examine changes in cortisol and beta-endorphin levels, as well as brain activity and functional connectivity during task performance, to explore potential mechanisms associated with treatment response.

Participants will:

  1. Receive either ASIST or TAU.
  2. Complete psychological, clinical, and behavioral assessments before and after treatment.
  3. Undergo measurements of cortisol and beta-endorphin levels.
  4. Complete tasks during brain imaging assessments to measure brain activity and functional connectivity.
02

Conditions studied

  • Non-suicidal Self-injury (NSSI)
  • Adolescent

Keywords

  • Non-Suicidal Self-Injury (NSSI)
  • Adolescent
  • Adolescent Self-Injury Intervention Skills Training
  • Psychological Intervention
  • Treatment Response
  • Neurobiological Mechanisms
  • Functional Brain Connectivity
  • Machine Learning
03

In context

Self-Injurious Behavior

303 studies on the registry are indexed under Self-Injurious Behavior; 105 are open to participants now.

This study's planned enrollment of 100 is above the median of 70 across 254 interventional studies indexed under Self-Injurious Behavior.

Browse Self-Injurious Behavior studies →

Lead sponsor

Seoul National University is the lead sponsor of 32 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adolescents aged 12 to 17 years.
  • Adolescents who meet the diagnostic criteria for non-suicidal self-injury (NSSI) and report at least one episode of self-injurious behavior within the past month.
  • Adolescents who report at least one episode of self-injurious behavior within the past year, as assessed by the Self-Harm Inventory (SHI).
  • Participants currently taking psychiatric medication must have maintained a stable dosage for at least one month prior to enrollment.

Exclusion criteria

Exclusion Criteria:

  • History of psychotic disorders, including schizophrenia, or bipolar disorder.
  • History of eating disorders.
  • Presence of developmental disorders, including autism spectrum disorder.
  • History of alcohol or substance abuse within the past six months.
  • Presence of coexisting medical or neurological conditions.
  • Changes in psychiatric medication dosage within one month prior to enrollment.
  • History of an actual suicide attempt within the past year, as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Adolescent Self-Injury Intervention Skills Training (ASIST)

    Participants assigned to this arm will receive Adolescent Self-Injury Intervention Skills Training (ASIST), a structured psychological intervention developed for adolescents who engage in non-suicidal self-injury. The program consists of four sessions delivered over four weeks and incorporates cognitive behavioral therapy, emotion regulation, stress coping skills, and interpersonal skills training. The sessions focus on understanding self-injury and developing safety plans, identifying and modifying negative automatic thoughts, improving emotional awareness and regulation, and developing adaptive stress coping strategies. Participants who continue to demonstrate clinically significant difficulties at the four-week follow-up assessment may receive two additional advanced sessions targeting cognitive biases and difficulties identifying and expressing emotions.

    Behavioral: Adolescent Self-Injury Intervention Skills Training (ASIST)

  • Active comparator
    Treatment as Usual (TAU)

    Participants assigned to this arm will receive treatment as usual (TAU) for non-suicidal self-injury over four weeks. Treatment will consist of routine clinical interventions typically provided to adolescents presenting with self-injurious behaviors in child and adolescent psychiatric settings, including psychoeducation on self-injury prevention, safety planning, behavioral chain analysis, counseling, and supportive psychotherapy. Participants will undergo the same baseline, post-treatment, and four-week follow-up assessments as those in the ASIST group.

    Behavioral: Treatment as Usual (TAU)

Interventions

  • BehavioralAdolescent Self-Injury Intervention Skills Training (ASIST)

    ASIST is a structured psychological intervention developed for adolescents who engage in non-suicidal self-injury. The program consists of four sessions delivered over four weeks, focusing on: (1) understanding self-injury, behavioral chain analysis, and safety planning; (2) identifying and modifying automatic thoughts, core beliefs, and rumination; (3) improving emotional awareness, expression, and regulation; and (4) developing stress management, coping, and interpersonal communication skills. The intervention incorporates cognitive behavioral and emotion regulation strategies. Participants with persistent clinically significant difficulties at the four-week follow-up may receive two additional sessions addressing cognitive and interpretation biases and difficulties identifying and expressing emotions.

  • BehavioralTreatment as Usual (TAU)

    Participants assigned to the TAU group will receive routine clinical care for non-suicidal self-injurious behavior over a 4-week period. Depending on their individual clinical needs, treatment may include psychoeducation, safety planning, behavioral chain analysis, counseling, and supportive psychotherapy, consistent with usual care practices in child and adolescent psychiatry.

06

What researchers measure

Primary outcomes

  1. Change in Self-Harming Behaviors as Assessed by the Self-Harm Inventory (SHI)

    Self-harming behaviors will be assessed using the Korean version of the Self-Harm Inventory (SHI), a 20-item self-report questionnaire evaluating the frequency of self-harming and self-destructive behaviors. Participants rate each item based on their experiences over the past 4 weeks or their current experiences, using a 4-point Likert scale ranging from 1 (almost never) to 4 (always). Total scores range from 20 to 80, with higher scores indicating more frequent or severe self-harming behaviors. Changes in total SHI scores will be evaluated from baseline (V1) to post-intervention (V5) and from baseline (V1) to the 4-week follow-up (V6).

    Time frame: Baseline (V1, Week 1), Post-intervention (V5, Weeks 4-5), and 4-week Follow-up (V6, Weeks 8-9)

Secondary outcomes

  1. Change in Frequency of Non-Suicidal Self-Injury as Assessed by the Korean Inventory of Statements About Self-Injury (K-ISAS)

    The functions of non-suicidal self-injury (NSSI) will be assessed using the K-ISAS, a self-report questionnaire evaluating NSSI behaviors and their underlying functions. The assessment of NSSI functions consists of 39 items measuring 13 functions of NSSI, categorized into intrapersonal and interpersonal functions. Each item is rated on a 3-point Likert scale ranging from 0 (not relevant) to 2 (very relevant), yielding a total score ranging from 0 to 78. Higher scores indicate greater endorsement of NSSI functions. Changes in total scores will be evaluated from baseline (V1) to post-intervention (V5) and from baseline (V1) to the 4-week follow-up (V6).

    Time frame: Baseline (V1, Week 1), Post-intervention (V5, Weeks 4-5), and 4-week Follow-up (V6, Weeks 8-9)

  2. Change in Severity of Suicidal Ideation as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)

    Suicidal ideation severity will be assessed using the C-SSRS, assessing suicidal ideation and behavior. Suicidal ideation severity is evaluated using five yes/no items and scored on a scale from 0 (no suicidal ideation) to 5 (active suicidal ideation with a specific plan and intent). Higher scores indicate greater severity of suicidal ideation. A suicidal ideation severity score of 4 or higher will be used as the cutoff for elevated suicide risk in this study. Changes in suicidal ideation severity scores will be evaluated from baseline (V1) to post-intervention (V5) and from baseline (V1) to the 4-week follow-up (V6).

    Time frame: Baseline (V1, Week 1), Post-intervention (V5, Weeks 4-5), and 4-week Follow-up (V6, Weeks 8-9)

  3. Change in Emotion Regulation Difficulties as Assessed by the Difficulties in Emotion Regulation Scale-16 (DERS-16)

    DERS-16 is a 16-item self-report questionnaire designed to assess difficulties in emotion regulation across five domains: nonacceptance of emotional responses, difficulties engaging in goal-directed behavior, impulse control difficulties, limited access to emotion regulation strategies, and lack of emotional clarity. Each item is rated on a 5-point Likert scale ranging from 0 (almost never) to 5 (almost always), yielding a total score ranging from 16 to 80. Higher scores indicate greater difficulties in emotion regulation. Changes in total DERS-16 scores will be evaluated from baseline (V1) to post-intervention (V5) and from baseline (V1) to the 4-week follow-up (V6).

    Time frame: Baseline (V1, Week 1), Post-intervention (V5, Weeks 4-5), and 4-week Follow-up (V6, Weeks 8-9)

  4. Change in Impulsivity as Assessed by the Barratt Impulsiveness Scale-Brief (BIS-Brief)

    The BIS-Brief is an 8-item self-report questionnaire designed to assess impulsivity as a unidimensional construct. Each item is rated on a 4-point Likert scale ranging from 0 (never) to 3 (almost always), yielding a total score ranging from 0 to 24. Higher scores indicate greater impulsivity. Changes in total BIS-Brief scores will be evaluated from baseline (V1) to post-intervention (V5) and from baseline (V1) to the 4-week follow-up (V6).

    Time frame: Baseline (V1, Week 1), Post-intervention (V5, Weeks 4-5), and 4-week Follow-up (V6, Weeks 8-9)

  5. Change in Depressive Symptom Severity as Assessed by the Children's Depression Rating Scale-Revised (CDRS-R)

    The CDRS-R is a 17-item clinician-rated scale to measure the severity of depression of children and adolescents. The scale evaluates emotional, cognitive, behavioral, and somatic symptoms associated with depression. Depression symptoms are rated on a 5-point scale from 1 to 5 for sleep, appetite, and tempo of speech items and a 7-point scale from 1 to 7 for remaining 14 items. Total scores range from 17 (normal) to 113 (severe depression), with higher scores indicating greater severity of depressive symptoms. Changes in total CDRS-R scores will be evaluated from baseline (V1) to post-intervention (V5) and from baseline (V1) to the 4-week follow-up (V6).

    Time frame: Baseline (V1, Week 1), Post-intervention (V5, Weeks 4-5), and 4-week Follow-up (V6, Weeks 8-9)

  6. Change in Anxiety Symptoms as Assessed by the Screen for Child Anxiety Related Emotional Disorders (SCARED)

    The SCARED is a 41-item questionnaire designed to assess anxiety symptoms in children and adolescents across five domains: panic/somatic symptoms, generalized anxiety, separation anxiety, social anxiety, and school avoidance. Each item is rated on a 3-point Likert scale ranging from 0 (not true or hardly ever true) to 2 (very true or often true), yielding a total score ranging from 0 to 82. Higher scores indicate greater severity of anxiety symptoms. A total score of 25 or higher suggests the possible presence of an anxiety disorder, while a score of 30 or higher indicates increased likelihood of an anxiety disorder. Changes in total SCARED scores will be evaluated from baseline (V1) to post-intervention (V5) and from baseline (V1) to the 4-week follow-up (V6).

    Time frame: Baseline (V1, Week 1), Post-intervention (V5, Weeks 4-5), and 4-week Follow-up (V6, Weeks 8-9)

07

Study locations

1 of 1 sites recruiting
08

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07910110
Lead sponsor
Seoul National University
Collaborators
National Research Foundation of Korea
Responsible party
Jae-Won Kim (Professor, Seoul National University) — Principal investigator
First posted
Nov 2, 2026
Start date
Dec 15, 2021
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Jae-Won Kim, MD, PhD
Contact
kimjw412@snu.ac.kr
82-2-2072-3648
Jae-Won Kim, MD, PhD
principal investigator · Seoul National University and Seoul National University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion